ABOUT THE EXPERT

Paul G. Richardson,

MD

Clinical Program Leader and Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
RJ Corman Professor of Medicine
Harvard Medical School
Boston, MA

Paul G. Richardson, MD: After certification in Internal Medicine, Hematology and Medical Oncology, as well as working in Cancer Pharmacology from 1994 onwards at the Dana-Farber Cancer Institute (DFCI), Dr Richardson joined the Jerome Lipper Multiple Myeloma Center in 1999, was appointed clinical director in 2001, and led the development of key novel agents in the treatment of myeloma, including bortezomib, lenalidomide, panobinostat, ixazomib and pomalidomide. Subsequent studies have focused on next-generation novel drugs, including histone deacetylase inhibitors such as panobinostat and other small molecules such as the second-generation proteasome inhibitors NPI 0052 (also known as marizomib) and MLN 9708 (now known as ixazomib), with the goal of further improving patient outcome. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab for the treatment of both untreated and relapsed myeloma. 

Previously, Dr Richardson’s senior investigator role in the Velcade as Initial Standard Therapy in Multiple Myeloma: Assessment with Melphalan and Prednisone (VISTA) trial comparing bortezomib in combination with melphalan and prednisone vs melphalan and prednisone alone as part of an international phase 3 trial established bortezomib, melphalan, and prednisone (VMP) as a new treatment standard in patients not eligible for stem cell transplant. At present, his major effort has been focused on the Intergroupe Francophone Myelome (IFM)/DFCI clinical trial in newly diagnosed patients eligible for stem cell transplant treated with lenalidomide, bortezomib, and dexamethasone (so-called RVD). This regimen has generated an unprecedented response rate, leading to its adoption in this international study (as well as in the United States and elsewhere), which incorporates genomic and proteomic evaluation to establish a future platform for tailored therapy. Other important contributions include the management of treatment-emergent neuropathy in myeloma. Similarly, the development of defibrotide for the treatment and prevention of hepatic veno-occlusive disease following stem cell transplantation has been aimed at improving therapeutic outcome, with defibrotide emerging as the first agent approved for this unmet medical need.

Dr Richardson has published extensively, having authored or coauthored more than 360 original articles and 280 reviews, chapters, and editorials in peer-reviewed journals. In addition to holding positions on the editorial boards of leading journals, he is prior chairman of the Multiple Myeloma Research Consortium (MMRC), Clinical Trials Core, a position that he held for 5 years as part of a rotating tenure, and for which he continues as a member of the Steering and Project Review Committee. He was also a member of the American Society of Clinical Oncology (ASCO) Hematologic Malignancies Subcommittee for the required 1-year term, followed by a 1-year term on the ASCO Internet Cancer Information Committee in 2017. He was appointed chair of the Alliance Myeloma Committee in 2011 and continues in this role today.

Honors include the George Canellos Award for Excellence in Clinical Research and Patient Care, and The Tisch Outstanding Achievement Award for Clinical Research, as well an honorary Fellowship of the Royal College of Physicians (UK), given in recognition for international contributions in multiple myeloma and stem cell transplantation. He was a co-recipient of the prestigious Warren Alpert Foundation Prize in Medicine in recognition of the successful therapeutic targeting of the ubiquitin-proteasome pathway.  He was also a co-recipient of the Accelerator Award for contributions to clinical research and patient enrollment in MMRC studies, as well as for the Research Center of the Year Award in 2009, followed by a second award for Center of the Year in 2017.  He was ranked by Thomson Reuters ScienceWatch.com amongst the top 19 investigators at the DFCI for the most highly cited research in 2016.  Most recently, he was the co-recipient of the American Society of Hematology Ernest Beutler Prize for clinical science and translational research in the development of proteasome inhibition as an effective treatment strategy for multiple myeloma in 2015; the COMy Award for multiple myeloma research (Paris, France) in 2016, and the International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award in 2017.

CONTRIBUTING ARTICLES